Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,198,346 papers from all fields of science
Search
Sign In
Create Free Account
Alendronate
Known as:
4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
, (4-Amino-1-hydroxybutylidene)bisphosphonic Acid
, Aminohydroxybutane Bisphosphonate
Expand
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
21 relations
Narrower (3)
5-FdU-alendronate
Alendronate Sodium
Maxmarvil
Alendronic acid
Alendronic acid 35 MG Oral Tablet
Drug Allergy
Esophageal Achalasia
Expand
Broader (3)
Bone Density Conservation Agents
Diphosphonates
antagonists & inhibitors
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Alendronate Use Among 812 Women: Prevalence of Gastrointestinal Complaints, Noncompliance with Patient Instructions, and Discontinuation
B. Ettinger
2015
Corpus ID: 74232163
ABSTRACT: The objective of this study was to determine the extent to which women who receive alendronate therapy for osteoporosis…
Expand
2012
2012
Proposed Title : Update on denosumab in postmenopausal osteoporosis – recent clinical data
2012
Corpus ID: 30528480
2010
2010
More on the Resolution of Bisphosphonate-associated Osteonecrosis of the Jaw
K. Tsai
,
Chin-Sheng Huang
,
Guan-min Huang
,
Chen-Tung Yu
Journal of Rheumatology
2010
Corpus ID: 42374317
To the Editor: We thank Drs. Duck-An Kim and Think-You Kim for their comments about our article1. We agree that hepatitis test…
Expand
2009
2009
Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys
G. Stroup
,
S. Sushanth Kumar
,
C. Jerome
Calcified Tissue International
2009
Corpus ID: 7429568
The cysteine protease cathepsin K is involved in osteoclast-mediated bone resorption. We evaluated the effect of daily oral…
Expand
2004
2004
Potentiometric determination of alendronate in pharmaceutical formulations
Andréia de Haro Moreno
,
H. Pezza
,
L. Pezza
2004
Corpus ID: 91970814
A simple, precise, fast and low-cost potentiometric method for alendronate determination in pharmaceutical formulations has been…
Expand
2003
2003
The effect of alendronate in the treatment of postmenopausal osteoporosis.
Z. Rozkydal
,
P. Janícek
Bratislava Medical Journal
2003
Corpus ID: 25438635
OBJECTIVES The aim of the study was the evaluation of the effect of alendronate in the treatment of postmenopausal osteoporosis…
Expand
2000
2000
ALENDRONATE REDUCES OSTEOLYSIS INDUCED BY FLUID PRESSURE IN A RAT MODEL
J. Åstrand
2000
Corpus ID: 74331496
INTRODUCTION Particles, instability or fluid pressure have been proposed as mechanisms leading to periprosthetic bone resorption…
Expand
1996
1996
Three-year follow-up on effects of transdermal estrogen.
E. G. Lufkin
,
B. L. Riggs
Annals of Internal Medicine
1996
Corpus ID: 7016072
1996
1996
Monosodium 4‐Amino‐1‐hydroxy‐1,1‐butanediyldiphosphonate Trihydrate (Alendronate)
D. Vega
,
R. Baggio
,
M. Garland
1996
Corpus ID: 97809875
The cation in the title compound, Na+.C4H12NO7P2−.3H2O, has the expected zwitterionic character, with a terminal protonated amine…
Expand
1996
1996
Effects of alendronate on plasma calcium levels, urinary calcium excretion, and bone resorption markers in normal rats: comparison with elcatonin, synthetic eel calcitonin.
Yoshiaki Azuma
,
M. Chokki
,
Tomohiro Ohta
,
Mamoru Kiyoki
Endocrinology
1996
Corpus ID: 22310234
In normal rats given alendronate (0.01-6.25 mg/kg) or elcatonin (synthetic eel calcitonin; 0.32-8.0 U/kg), changes in urinary…
Expand